Leidos Gets Patent for Peptide-Class of Checkpoint Inhibitors

Leidos’ life sciences unit has secured a U.S. patent for its new peptide-based PD-1 checkpoint inhibitors developed for more targeted delivery of treatments.

The company said Thursday that the U.S. Patent and Trademark Office issued the patent for Leidos Health Life Sciences through the Patents 4 Patients program.

The program provides a faster review process for cancer immunotherapy-related patent applications.

Gabriel Gutierrez, Leidos researcher and one of the developers, said the team utilized tools used to fight cancer to develop the checkpoint inhibitors to fight infectious diseases such as malaria and HIV.

“Peptides represented an ideal tool to achieve our goal and this patent represents an important milestone for us,” he said.

Leidos said peptides enable researchers to provide more targeted delivery of treatments as they serve as a therapeutic platform that can be genetically engineered into vaccines, oncolytic viruses and cellular therapies.

You may also be interested in...

Paul Dillahay President

NCI Partners With Mercyhurst to Advance AI Platform; Paul Dillahay Quoted

NCI Information Systems has entered an academic partnership with Mercyhurst University to advance NCI’s artificial intelligence (AI) technology for the federal government. “We’re excited to work with Mercyhurst University to further augment the NCI Empower AI platform,” said Paul Dillahay, president and CEO of NCI and a 2020 Wash100 Award recipient.

James McFadyen VP

Former Leonardo DRS Exec James McFadyen Joins Fairbanks Morse as Aftermarket Business Lead

James McFadyen, formerly a vice president at Leonardo DRS' naval power systems group, has been named VP and general manager of the aftermarket business at Fairbanks Morse.

NuScale Power small modular nuclear reactor plant design

Fluor Plans to Support NuScale Reactor Project Through Potential $1.35B DOE Funding Vehicle

The Department of Energy has cleared a funding vehicle worth potentially $1.355B for a public power consortium-led project that includes construction of a small modular reactor plant by NuScale Power, which Fluor holds a majority stake in. Fluor said Monday it plans to support Utah Associated Municipal Power Systems and NuScale in establishing a clean-energy SMR system through UAMPS' Carbon Free Power Project.